The Trilogy valve. [Image from the JenaValve website] GlobalData analysts anticipate FDA approval for the JenaValve Trilogy TAVR device designed to treat aortic regurgitation (AR) this year.

The primary endpoint was mortality at 30 days. Secondary endpoints were in-hospital mortality, 1-year mortality, bleeding, major vascular complications, myocardial infarction, stroke, incidence of ...

At that time a heart murmur was first noted ... Demonstrating an Ascending Aortic Aneurysm, with Hyper-trophy of the Left Ventricle and Some Enlargement of the Left Atrium. On the 10th hospital ...

Wearable devices have come a long way from counting steps or heartbeats, with new tech offering the ability to track blood oxygenation, glucose levels and blood pressure – though its reliability ...

How did the doctors come to err so often? Their commonest stumble was a “functional” (i.e., not organic) heart murmur, of a type which Dr. Goldwater describes as “transitory, innocent.” ...

Jacob Marlowe underwent open heart surgery in October. The left-handed pitcher is on the road to recovery. Read about his journey.